东峰集团(601515) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 354,984,405.88, representing a decrease of 61.25% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 12,212,702.90, down 94.57% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,694,970.17, a decline of 98.58% compared to the previous year[5]. - Basic and diluted earnings per share were both CNY 0.01, reflecting a decrease of 91.67% year-on-year[5]. - Net profit for Q1 2024 was CNY 13,429,102.62, a decline of 94.2% compared to CNY 229,962,471.70 in Q1 2023[22]. - The company's operating revenue for Q1 2024 was ¥15,700,224.97, a significant decrease of 95.5% compared to ¥351,227,577.82 in Q1 2023[33]. - The net profit for Q1 2024 was a loss of ¥5,759,726.97, contrasting sharply with a net profit of ¥107,863,401.67 in Q1 2023[33]. - The company reported a total comprehensive income of -¥5,450,400.06 for Q1 2024, down from ¥107,863,401.67 in the same period last year[34]. Cash Flow - The net cash flow from operating activities was negative at CNY -556,836,666.93, indicating significant cash outflow[5]. - The net cash flow from operating activities for Q1 2024 was -CNY 556,836,666.93, worsening from -CNY 229,337,793.22 in Q1 2023[25]. - Cash inflow from operating activities totaled CNY 315,404,483.33 in Q1 2024, down from CNY 738,518,110.76 in Q1 2023[25]. - The cash flow from operating activities showed a net outflow of ¥96,677,852.46 in Q1 2024, compared to a net inflow of ¥104,053,653.67 in Q1 2023[35]. - The net cash flow from investing activities was -42,215,853.30 RMB, compared to a positive cash flow of 17,529,726.25 RMB in the previous period, indicating a significant decline in investment performance[26]. - The total cash and cash equivalents decreased by ¥604,347,951.85 in Q1 2024, compared to a decrease of ¥61,749,801.75 in Q1 2023[35]. Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 7,336,207,372.68, a decrease of 0.96% from the end of the previous year[6]. - The company's current assets totaled RMB 3,571,414,077.29, down from RMB 3,658,947,385.18, indicating a decrease of about 2.38%[15]. - The total liabilities as of Q1 2024 were CNY 1,267,097,655.76, a decrease from CNY 1,348,578,429.85 in the previous year[21]. - The company's total liabilities decreased to RMB 912,685,329.49 from RMB 1,001,455,760.72, reflecting a decline of approximately 8.84%[16]. - The total assets as of March 31, 2024, were 5,912,006,396.61 RMB, slightly down from 5,919,168,321.37 RMB at the end of 2023[30]. - The total liabilities decreased marginally to 469,209,036.76 RMB from 470,938,244.25 RMB, indicating stable financial leverage[30]. Shareholder Equity - Shareholders' equity attributable to the parent company was CNY 5,720,718,127.94, showing a slight increase of 0.16% from the previous year[6]. - Total equity attributable to shareholders was CNY 5,720,718,127.94, slightly up from CNY 5,711,424,032.00 in Q1 2023[21]. - The company's total equity as of March 31, 2024, was 5,442,797,359.85 RMB, down from 5,448,230,077.12 RMB, showing a slight reduction in shareholder value[31]. Strategic Changes and Market Conditions - The company is undergoing a strategic transformation focusing on new material business and I-type pharmaceutical packaging, which has led to significant changes in business structure[7]. - The decline in revenue and profit is attributed to economic weakness, insufficient demand, and intensified competition within the industry[7]. - The company reported a significant increase in research and development expenses, totaling CNY 20,711,898.71 in Q1 2024 compared to CNY 37,992,991.41 in Q1 2023[21]. - Research and development expenses for Q1 2024 were ¥1,580,788.30, down 66.4% from ¥4,696,235.37 in Q1 2023[33]. - The company incurred financial expenses of -¥6,670,983.81 in Q1 2024, compared to -¥386,051.11 in Q1 2023, indicating a significant increase in financial costs[33].